Video1 Lab Act

8/18/2019 Video1 Lab Act

1/20

Video #1

Rekam : Rabu, 9 – 10.30 wib (NO NGARET!!!!)

amea :

a" :

1. $oke : A%ka&. 'aak : *iddi+3. bu : A-a*/. Aak : odi. u"e: E2ia. 4a"ie u55u di %ua : "odi 6 2ia, 2eo 7 ke82a, a""ak*a 7 "e2a

ee #1

E2ia : (ma55i%) bu a-a (a di "oo a"ie 85 %a5i u55u)

A-a*iddi+aak : (ma"uk)

A%ka : e%ama a5i baak, ibu, "i%aka duduk.

A-a**iddi+ : ia5 dok, eima ka"i*

A%ka : ekea%ka ama "a8a a%ka, doke 8a5 "eda5 beu5a" di k%iik ii

E2ia : (5a"i* med eod) dok ii media% eod8a

A%ka : 8a maka"i* ("e8um :$) $e5a bu A-a* 31 a*u, 5uu ;A, dai

a%au baak8a de5a "iaa ama8a=

*iddi+ : *iddi+ dok

A%ka : eke


2/20

A%ka : 8a5 ii aak kedua bu=

A-a* : i 8a5 eama dook, 8a5 kedua umu8a "au a*u.

A%ka : ma"i* dimaka i% kb8a bu=

A-a* : "uda* be*ei dok "emea%au ibu beabea idak mau u8a aak %a5i "a8a "aaka


3/20

akai im%a "aami", u%a5 %eue 1&.0013.30 (NO NGARET!!, ka%au mau

dadai a""ak*a C amea :

a" :

1. $oke : 2eo&. uami: e2a3. "i : NV/. "i : a""ak*a (*8e*8oid). u"e : ida*. u"e : ke82a


4/20

A%5oi*m memi%i* koa"e"i (ma"uki di 2ideo)

dika"i da koaidika"i


5/20

1 Method can be used without restriction.

2 Advantages of method generally outweigh risks.

3 Method not usually recommended unless other, more appropriate methods are not available or not acceptable.

4 Method not to be used.

Condition Qualifier for

condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

Anemia halassemia 1 1 1 1 1 2

!ickle cell

disease

2 1 1 1 1 2

"ron#deficiency

anemia

1 1 1 1 1 2

$reast

disease

%amily history of

cancer

1 1 1 1 1 1

&urrent breast

cancer

4 4 4 4 4 1

$reast cancer in

past, no evidence

of disease for ' (

years

3 3 3 3 3 1

)ndiagnosedbreast mass

2 2 2 2 2 1

$enign breast

disease

1 1 1 1 1 1

&ervical &ervical 2 1 2 2 2 1


6/20


7/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

/riseofulvin

0/risactin

2 2 1 2 1 1

ifampin 0ifadin 3 3 2 3 1 1

All other

antibiotics

1 1 1 1 1 1

ndometrial cancer 1 1 1 1 4 4

ndometriosis 1 1 1 1 1 2

/allbladder

disease

Asymptomatic

gallstones

2 2 2 2 2 1

!ymptomatic

gallstones,

without

cholecystectomy

3 2 2 2 2 1

/allstones treated

with

cholecystectomy

2 2 2 2 2 1

regnancy#

related

2 1 1 1 1 1


8/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

cholestasis in

past

+ormone#related

cholestasis in

past

3 2 2 2 2 1

+eadaches 5onmigrainous 1 1 1 1 1 1

Migrainous

ithout aura, age

6 3( years

2 1 2 2 2 1

ithout aura, age

7 3( years

3 1 2 2 2 1

ith aura, any

age

4 2 2 2 2 1

+"89A"*! +igh risk 1 1 1 1 2 2

+"8 infected 1 1 1 1 2 2

A"*! 0without 1 1 1 1 3 3


9/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

drug interactions

+ypertension *uring prior

pregnancy, now

resolved

2 1 1 1 1 1

ell controlled 3 1 2 1 1 1

!ystolic $ 14-:

1(; mm +g ordiastolic $ ;-:

;; mm +g

3 1 2 1 1 1

!ystolic $ 71


10/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

&irrhosis, severe 4 3 3 3 3 1

umors, benign 4 3 3 3 3 1

umors,

malignant

4 3 3 3 3 1

8iral hepatitis,

carrier

1 1 1 1 1 1

8iral hepatitis,

active

4 3 3 3 3 1

>besity $M" 7 3- kg per

m22 1 1 1 1 1

>varian cancer 1 1 1 1 3 3

>varian cysts and benign tumors 1 1 1 1 1 1

elvic

inflammatory

disease

ast, with

subse?uent

pregnancy

1 1 1 1 1 1

ast, without 1 1 1 1 2 2


11/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

subse?uent

pregnancy

&urrent 1 1 1 1 4 4

ostabortion %irst trimester 1 1 1 1 1 1

!econd trimester 1 1 1 1 2 2

"mmediately after

septic abortion

1 1 1 1 4 4

ostpartum,

not

breastfeeding

6 2 days

postpartum

3 1 1 1 3 2

2 to 21 days 3 1 1 1 3 3

22 to 2@ days 1 1 1 1 3 3

' 2@ days 1 1 1 1 1 1

ostpartum,

breastfeeding

6 2 days

postpartum

4 3 3 3 3 2


12/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

2 to 2 days 4 3 3 3 3 3

2@ to 41 days 4 3 3 3 1 1

< weeks to <

months

3 1 1 1 1 1

' < months 2 1 1 1 1 1

!eiBure

disorder

ithout drug

interactions

1 1 1 1 1 1

!eCually

transmitted

disease

8aginitis 1 1 1 1 2 2

+igh risk 1 1 1 1 3 3

&urrent purulent

cervicitis,

chlamydialinfection, or

gonorrhea

1 1 1 1 4 4

!moking Age 6 3( years 2 1 1 1 1 1

Age 7 3( years, 6 3 1 1 1 1 1


13/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

1( cigarettes per

day

Age 7 3( years, 7

1( cigarettes per

day

4 1 1 1 1 1

!troke 4 2 3 2 2 1

!urgery Minor, withoutprolonged

immobiliBation

1 1 1 1 1 1

MaDor, without

prolonged

immobiliBation

2 1 1 1 1 1

MaDor, with

prolonged

immobiliBation

4 2 2 2 2 1

hyroid

disorders

!imple goiter,

hyperthyroidism,

hypothyroidism

1 1 1 1 1 1

)terine

fibroids

ithout distortion

of uterine cavity

1 1 1 1 1 1


14/20






condition

Combined

methods*

PROGESTIN-ONLY

PIL

L

INJECTIO

N

IMPLANT

† IUD

COPPER

IUD

ith distortion of

uterine cavity

1 1 1 1 4 4

8alvular heart

disease

)ncomplicated 2 1 1 1 1 1

&omplicated 4 1 1 1 2 2

8aricose veins 1 1 1 1 1 1

8enous

thrombosis

%amily history

0first#degree

relatives

2 1 1 1 1 1

!uperficial

thrombophlebitis

2 1 1 1 1 1

ast *89 4 2 2 2 2 1

&urrent *89 4 3 3 3 3 1

EFEstrogen/progestin pill, patch, or ring .

GFNot available in the United States.


15/20

WH ! World Health rgani"ation# $U% ! intrauterine device# H$& ! human immunodeficienc' virus# ($%S !

ac)uired immunodeficienc' s'ndrome# + ! blood pressure# $ ! bod' mass inde-# %&. ! deep venous

thrombosis# +E ! pulmonar' embolism.

(dapted ith permission from edical Eligibilit' Criteria for Contraceptive Use0 1rd ed0 2eneva3 World Health

rgani"ation, 4556371, 7819:50 (ccessed %ecember 44, 455;, at3http3//0ho0int/reproductive<

health/publications/mec/mec0pdf .

#"ee & D ke"imu%a : *8oid di"ea"e bi"a ake 85 maa a'=

NV : "uda* dok, "a8a akai i% kombia"i

http://www.who.int/reproductive-health/publications/mec/mec.pdfhttp://www.who.int/reproductive-health/publications/mec/mec.pdfhttp://www.who.int/reproductive-health/publications/mec/mec.pdfhttp://www.who.int/reproductive-health/publications/mec/mec.pdf


16/20

Veo : kaa be*ei da keaa 8a bu=

N2 : "ekia bu%a 85 %a%u, "a8a e8aa a%e5i dok

Veo : oo. A%e5i 8a, bu kaa eak*i ka%i me"=

NV : "a8a "uda* *ai ke i5a me" dok

Veo : wa*, ka%au mau a"a5 >' waku8a "uda* ea, aaka* ibu "uda*

meeuka mau me55uaka 85 maa=

NV : be%um dok, "a8a i5i me55uaka miii% ai aaka* %ebi* eeki

daiada @$ dok=

Veo : di media% eod ibu idak ada iwa8a e8aki bea da oea"i, bea

bu=

N2 : bea dok

Veo : uuk %ebi* eeki da e-"ie meuu "a8a baik8a ibu me55uaka @$

kaea eama adi ibu a%e5i, %a%u @$ e"ea"e kebe*a"i%a8a %ebi* i55i bu.@uk miii% "edii *au" diko"um"i "eia *ai da%am waku 8a5 "ama. Bika ibu

u8a ba8ak ke5iaa aku8a %ua da e82a : (ma"uk) ibu "i%aka ma"uk ke "ii.

N2 : (ke ua5a %ai bae5 ke82a)

Veo : "e%a' "ebe%um8a=

RiFki : be%um dok.

Veo : di "ii eu%i" ibu ekea *8o*8oid "eme


17/20

RiFki : bea dok

Veo : koa"e"i aa ibu eak*i me"=

RiFki : "uda* "ekia dua mi55u 8a5 %a%u dok

Veo : eak*i be*ubu5a akai e5ama 5ak bu=

RiFki : ake 5ak 8a a=

e2a : e55ak dok

Veo : >a%au idak, ibu idak bi"a me55uaka >'8a "ekaa5, kia u55u dua

mi55u %a5i aaka* ai e" ke*ami%a8a o"ii aau idak. Tai ibu bi"a memi%i*

"ekaa5 a5a muda* ema"a5a8a ai

RiFki : ka%au ima iu a*a beaa %ama 8a dok=Veo : ima bi"a "amai 3 a*u.

e2a : iu a"a58a 5imaa 8a=

Veo : ai ada abu5 kei% m dia"a5 di%e5a aa" ibu8a, i"i8a *omoe

mee5a* ke*ami%a ak

e2a : 5imaa ma=

RiFki : "a8a mau im%a a


18/20


19/20


20/20

Documents

Video1 Lab Act